23.40
+0.2(+0.86%)
Currency In USD
| Previous Close | 23.2 |
| Open | 23.15 |
| Day High | 23.57 |
| Day Low | 22.87 |
| 52-Week High | 40.55 |
| 52-Week Low | 12.21 |
| Volume | 429,757 |
| Average Volume | 481,719 |
| Market Cap | 655.13M |
| PE | -5.33 |
| EPS | -4.39 |
| Moving Average 50 Days | 23.14 |
| Moving Average 200 Days | 19.97 |
| Change | 0.2 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $1,376.47 as of September 13, 2025 at a share price of $23.4. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $1,546.6 as of September 13, 2025 at a share price of $23.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Participation in September Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 8:15 PM GMT
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
GlobeNewswire Inc.
May 27, 2025 8:15 PM GMT
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from th
Anaptys Announces Stock Repurchase Plan
GlobeNewswire Inc.
Mar 24, 2025 1:15 PM GMT
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repur